- Home
- SUPN vs PTEN Comparison
SUPN vs PTEN Comparison
Compare SUPN & PTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- PTEN
- Stock Information
- Founded
- SUPN 2005
- PTEN 1978
- Country
- SUPN United States
- PTEN United States
- Employees
- SUPN N/A
- PTEN N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- PTEN Oil & Gas Production
- Sector
- SUPN Health Care
- PTEN Energy
- Exchange
- SUPN Nasdaq
- PTEN Nasdaq
- Market Cap
- SUPN 2.0B
- PTEN 2.1B
- IPO Year
- SUPN 2012
- PTEN 1993
- Fundamental
- Price
- SUPN $42.00
- PTEN $5.38
- Analyst Decision
- SUPN Buy
- PTEN Buy
- Analyst Count
- SUPN 2
- PTEN 11
- Target Price
- SUPN $41.00
- PTEN $8.27
- AVG Volume (30 Days)
- SUPN 1.0M
- PTEN 8.7M
- Earning Date
- SUPN 08-05-2025
- PTEN 07-23-2025
- Dividend Yield
- SUPN N/A
- PTEN 5.94%
- EPS Growth
- SUPN 1411.53
- PTEN N/A
- EPS
- SUPN 1.14
- PTEN N/A
- Revenue
- SUPN $665,125,000.00
- PTEN $5,019,214,000.00
- Revenue This Year
- SUPN N/A
- PTEN N/A
- Revenue Next Year
- SUPN $15.74
- PTEN N/A
- P/E Ratio
- SUPN $37.58
- PTEN N/A
- Revenue Growth
- SUPN 5.55
- PTEN N/A
- 52 Week Low
- SUPN $29.16
- PTEN $5.12
- 52 Week High
- SUPN $43.73
- PTEN $9.66
- Technical
- Relative Strength Index (RSI)
- SUPN 69.63
- PTEN 39.28
- Support Level
- SUPN $40.26
- PTEN $5.25
- Resistance Level
- SUPN $43.73
- PTEN $5.76
- Average True Range (ATR)
- SUPN 1.80
- PTEN 0.25
- MACD
- SUPN 0.31
- PTEN -0.01
- Stochastic Oscillator
- SUPN 84.13
- PTEN 14.44
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About PTEN Patterson-UTI Energy Inc.
Patterson-UTI Energy Inc is one of the substantial land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. The company operates under three reportable business segments: (i) drilling services, (ii) completion services, and (iii) drilling products. It also provides directional drilling services and tool rental services in united states onshore oil and gas basins.